Statins and modulation of oxidative stress

Toxicology Mechanisms and Methods

Volumn 15, Issue 2, 2005, Pages 61-92

  Bełtowski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Hydroxymethylglutaryl coenzyme A Reductase Inhibitors; Isoprenoids; NADPH Oxidase; Oxidative Stress; Paraoxonase; Reactive Oxygen Species; Ubiquinone

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 5 HYDROXYFLUVASTATIN; 6 HYDROXYFLUVASTATIN; ANGIOTENSIN; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; CYTOCHROME P450; CYTOCHROME P450 2C; DOCOSAHEXAENOIC ACID; DOLICHOL; DRUG METABOLITE; ENDOTHELIN 1; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; FREE RADICAL; GERANYLGERANYL PYROPHOSPHATE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCAVENGER; SIMVASTATIN; UBIQUINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; FLU LIKE SYNDROME; GLOMERULONEPHRITIS; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY CELL; ISCHEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIVER TOXICITY; MITOCHONDRIAL ENCEPHALOPATHY; MYALGIA; MYOPATHY; MYOSITIS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOPOROSIS; OXIDATION; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PHAGOCYTE; PLEIOTROPY; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; RHABDOMYOLYSIS; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES;

EID: 18344396067     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520590918766     Document Type: Review

References (369)

1. Abid, M. R., Tsai, J. C., Spokes, K. C., Deshpande, S. S., Irani, K. and Aird, W. C. 2001. Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. FASEB J. 15:2548-2550.
2. Alfon, J., Guasch, J. F., Berrozpe, M., and Badimon, L. 1999. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 145:325-331.
3. Almog, Y. 2003. Statins, inflammation, and sepsis: hypothesis. Chest 124:740-743.
4. Alvarez De Sotomayor, M., Herrera, M. D., Marhuenda, E., and Andriantsitohaina, R. 2000. Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br. J. Pharmacol. 131:1179-1187.
5. Appelkvist, E. L., Edlund, C., Low, P., Schedin, S., Kalen, A., and Dallner, G. 1993. Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. Clin. Invest. 71:S97-S102.
6. Arnaiz, S. L., Travacio, M., Llesuy, S., and Boveris, A. 1995. Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim. Biophys. Acta 1272:175-180.
7. Aviram, M., Dankner, G., Cogan, U., Hochgraf, E., and Brook, J. G. 1992. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 41:229-235.
8. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., and Rosenblat, M. 2000. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517.
9. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C. L., Newton, R. S., and La Du, B. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26:892-904.
10. Aviram, M., Rosenblat, M., Bisgaier, C. L., and Newton, R.S. 1998. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138:271-280.
11. Backes, J. M., and Howard, P. A. 2003. Association of HMG-CoA reductase inhibitors with neuropathy. Ann. Pharmacother. 37:274-278.
12. Bae, J. H., Bassenge, E., Lee, H. J., Park, K. R., Park, C. G., Park, K. Y., Lee, M. S., and Schwemmer, M. 2001. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis 158:165-171.
13. Balogh, Z., Fulop, P., Seres, I., Harangi, M., Katona, E., Kovacs, P., Kosztaczky, B., and Paragh, G. 2001. Effects of simvastatin on serum paraoxonase activity. Clin. Drug Invest. 21:505-510.
14. Bandoh, T., Mitani, H., Niihashi, M., Kusumi, Y., Kimura, M., Ishikawa, J., Totsuka, T., Sakurai, I., and Hayashi, S. 2000. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J. Cardiovasc. Pharmacol. 35:136-144.
15. Bandoh, T., Sato, E. F., Mitani, H., Nakashima, A., Hoshi, K., and Inoue, M. 2003. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol. Pharm. Bull. 26:818-822.
16. Bargossi, A. M., Grossi, G., Fiorella, P. L., Gaddi, A., Di Giulio, R., and Battino, M. 1994. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors, Mol. Aspects Med. 15(Supp):S187-S193.
17. Bauer, D. C. 2003. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int. 14:273-282.
18. Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., and Ertl, G. 2001. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 104:982-985.
19. Beck, P., Wysowski, D. K., Downey, W., and Butler-Jones, D. 2003. Statin use and the risk of breast cancer. J. Clin. Epidemiol. 56:280-285.
20. Becuwe, P., Bianchi, A., Keller, J. M., and Dauca, M. 1999. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem. Pharmacol. 58:1025-1033.
21. Bełtowski, J., Wojcicka, G., and Jamroz, A. 2002a. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol. J. Pharmacol. 54:661-671.
22. Bełtowski, J., Wojcicka, G., Mydlarczyk, M., and Jamroz, A. 2002b. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol. J. Pharmacol. 54:143-150.
23. Bełtowski, J., Wojcicka, G., Mydlarczyk, M., and Jamroz, A. 2002c. The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity. J. Physiol. Pharmacol. 53:463-475.
24. Bełtowski, J., Wojcicka, G., and Jamroz, A. 2004. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J. Cardiovasc. Pharmacol. 43:121-127.
25. Berkels, R., Nouri, S. K., Taubert, D., Bartels, H., Roesen, P., Roesen, R., and Klaus, W. 2003. The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium. J. Cardiovasc. Pharmacol. 42:356-363.
26. Bernini, F., Scurati, N., Bonfadini, G., and Fumagalli, R. 1995. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol. 15:1352-1358.
27. Berthou, L., Duverger, N., Emmanuel, F., Langouet, S., Auwerx, J., Guillouzo, A., Fruchart, J. C., Rubin, E., Denefle, P., Staels, B., and Branellec, D. 1996. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest. 97:2408-2416.
28. Blaha, V., Zadak, Z., Solichova, D., Bratova, M., and Havel, E. 1998. Hypocholesterolemic effect of pravastatin is associated with increased content of antioxidant vitamin-E in cholesterol fractions. Acta Med. 41:87-90.
29. Bleske, B. E., Willis, R. A., Anthony, M., Casselberry, N., Datwani, M., Uhley, V. E., Secontine, S. G., and Shea, M. J. 2001. The effect of pravastatin and atorvastatin on coenzyme Q10. Am. Heart J. 142:E2.
30. Boger, R. H., Bode-Boger, S. M., Brandes, R. P., Phivthong-ngam, L., Bohme, M., Nafe, R., Mugge, A., and Frolich, I. C. 1997. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 96:1282-1290.
31. Boger, R. H., Bode-Boger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., and Cooke, J. P. 1998. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847.
32. Bokoch, G. M., and Prossnitz, V. 1992. Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J. Clin. Invest. 89:402-408.
33. Bolego, C., Baetta, R., Bellosta, S., Corsini, A., and Paoletti, R. 2002. Safety considerations for statins. Curr. Opin. Lipidol. 13:637-644.
34. Brandes, R. P., Beer, S., Ha, T., and Busse, R. 2003. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23:1794-1800.
35. Bravo, L., Herrera, M. D., Marhuenda, E., and Perez-Guerrero, C. 1998. Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats. Gen. Pharmacol. 30:331-336.
36. Brown, B. G., Zhao, X. Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., Frohlich, J., and Albers, J. J. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345:1583-1592.
37. Bureau, F., Desmet, C., Melotte, D., Jaspar, F., Volanti, C., Vanderplasschen, A., Pastoret, P. P., Piette, J., and Lekeux, P. 2002. A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-κB inhibition. J. Immunol. 168:5318-5325.
38. Cai, H., Griendling, K. K., and Harrison, D. G. 2003. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24:471-478.
39. Caillard, S., Leray, C., Kunz, K., Gachet, C., Offner, M., Wiesel, M. L., Hannedouchte, T.H., Cazenave, J. P., and Moulin, B. 2000. Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients. Transplant Proc. 32:2787-2788.
40. Cardillo, C., Kilcoyne, C. M., Cannon, R. O. 3rd, Quyyumi, A. A., and Panza, J. A. 1997. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30:57-63.
41. Carneado, J., Alvarez de Sotomayor, M., Perez-Guerrero, C., Jimenez, L., Herrera, M. D., Pamies, E., Martin-Sanz, M. D., Stiefel, P., Miranda, M., Bravo, L., and Marhuenda, E. 2002. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J. Hypertens. 20:429-437.
42. Ceriello, A., Taboga, C., Tonutti, L., Quagliaro, L., Piconi, L., Bais, B., Da Ros, R., and Motz, E. 2002. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218.
43. Chamberlain, L. H. 2001. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 507:357-361.
44. Chaput, E., Maubrou-Sanchez, D., Bellamy, F. D., and Edgar, A. D. 1999. Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with α-tocopherol. Lipids 34:497-502.
45. Chariot, P., Abadia, R., Agnus, D., Danan, C., Charpentier, C., and Gherardi, R. K. 1993. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. 94:109-110.
46. Chen, F. C., Hsu, H. C., and Lee, Y. T. 1997a. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Cardiovasc. Drug Ther. 11:787-793.
47. Chen, H., Ikeda, U., Shimpo, M., Ikeda, M., Minota, S., and Shimada, K. 2000. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36:923-928.
48. Chen, L., Haught, W. H., Yang, B., Saldeen, T. G., Parathasarathy, S., and Mehta, J. L. 1997b. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol. 30:569-575.
49. Cherry, N., Mackness, M., Durrington, P., Povey, A., Dippnall, M., Smith, T., and Mackness, B. 2002. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763-764.
50. Cheung, M. C., Zhao, X. Q., Chait, A., Albers, J. J., and Brown, B. G. 2001. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vasc. Biol. 21:1320-1326.
51. Chong, P. H., Seeger, J. D., and Franklin, C. 2001. Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med. 111:390-400.
52. Christ, M., Bauersachs, J., Liebetrau, C., Heck, M., Gunther, A., and Wehling, M. 2002. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 51:2648-2652.
53. Clarke, R., and Armitage, J. 2002. Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials. Cardiovasc. Drugs Ther. 16:411-415.
54. Corsini, A., Raiteri, M., Soma, M., Fumagalli, R., and Paoletti, R. 1991. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol. Res. 23:173-180.
55. Crane, F. L. 2001. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 20: 591-598.
56. Crisby, M., Nordin-Fredriksson, G., Shah, P. K., Yano, J., Zhu, J., and Nilsson, J. 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103:926-933.
57. Dallner, G., and Sindelar, P. J. 2000. Regulation of ubiquinone metabolism. Free Radic. Biol. Med. 29:285-294.
58. 2α is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17:3230-3235.
59. Davidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkema, R., Fayyad, R., and Black, D. 1997. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am. J. Cardiol. 79:1475-1481.
60. Day, A. P., Bellavia, S., Jones, O. T., and Stansbie, D. 1997. Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. Ann. Clin. Biochem. 34:269-275.
61. Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., and James, R. W. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277:4301-4308.
62. Deakin, S., Leviev, I., Guernier, S., and James, R. W. 2003. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23:2083-2089.
63. De Caterina, R., Cipollone, F., Filardo, F. P., Zimarino, M., Bernini, W., Lazzerini, G., Bucciarelli, T., Falco, A., Marchesani, P., Muraro, R., Mezzetti, A., and Ciabattoni, G. 2002. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106:2543-2549.
64. Dechend, R., Fiebeler, A., Park, J. K., Muller, D. N., Theuer, J., Mervaala, E., Bieringer, M., Gulba, D., Dietz, R., Luft, F. C., and Haller, H. 2001a. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104:576-581.
65. Dechend, R., Fiebler, A., Lindschau, C., Bischoff, H., Muller, D., Park, J. K., Dietz, R., Haller, H., and Luft, F. C. 2001b. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am. J. Hypertens. 14:55S-61S.
66. Delbosc, S., Cristol, J. P., Descomps, B., Mimran, A., and Jover, B. 2002a. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 40:142-147.
67. Delbosc, S., Morena, M., Djouad, F., Ledoucen, C., Descomps, B., and Cristol, J. P. 2002b. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 40:611-617.
68. De Pinieux, G., Chariot, P., Ammi-Said, M., Louarn, F., Lejonc, J. L., Astier, A., Jacotot, B., and Gherardi, R. 1996. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 42:333-337.
69. de Rijke, Y. B., Bredie, S. J., Demacker, P. N., Vogelaar, J. M., Hak-Lemmers, H. L., and Stalenhoef, A. F. 1997. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17:127-133.
70. Desideri, G., Croce, G., Tucci, M., Passacquale, G., Broccoletti, S., Valeri, L., Santucci, A., and Ferri, C. 2003. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab. 88:5341-5347.
71. Diebold, B. A., Bhagavan, N. V., and Guillory, R. J. 1994. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim. Biophys. Acta. 1200:100-108.
72. Diep, Q. N., Amiri, F., Touyz, R. M., Cohn, J. S., Endemann, D., Neves, M. F., and Schiffrin, E. L. 2002. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 40:866-871.
73. Dimmeler, S., Aicher, A., Vasa, M., Mildner-Rihm, C., Adler, K., Tiemann, M., Rutten, H., Fichtlscherer, S., Martin, H., and Zeiher, A. M. 2001. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108:391-397.
74. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., and Zeiher, A. M. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605.
75. Di Napoli, P., Antonio Taccardi, A., Grilli, A., Spina, R., Felaco, M., Barsotti, A., and De Caterina, R. 2001. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc. Res. 51:283-293.
76. Dobrucki, L. W., Kalinowski, L., Dobrucki, I. T., and Malinski, T. 2001. Statin-stimulated nitric oxide release from endothelium. Med. Sci. Monit. 7:622-627.
77. Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P.A., Langendorfer, A., Stein, E. A., Kruyer, W., and Gotto, A. M. Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622.
78. Draude, G., Hrboticky, N., and Lorenz, R. L. 1999. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem. Pharmacol. 57:383-386.
79. Duerrschmidt, N., Wippich, N., Goettsch, W., Broemme, H. J., and Morawietz, H. 2000. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem. Biophys. Res. Commun. 269:713-717.
80. Durrington, P. N., Mackness, B., and Mackness, M. I. 2001. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:473-480.
81. Eid, H. M., Eritsland, J., Larsen, J., Arnesen, H., and Seljeflot, I. 2003. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279-284.
82. Endres, M., Laufs, U., Huang, Z., Nakamura, T., Huang, P., Moskowitz, M. A., and Liao, J. K. 1998. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 95:8880-8885.
83. Evans, M., Anderson, R. A., Graham, J., Ellis, G. R., Morris, K., Davies, S., Jackson, S. K., Lewis, M. J., Frenneaux, M. P., and Rees, A. 2000. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101:1773-1779.
84. Ferguson, E., Parthasarathy, S., Joseph, J., and Kalyanaraman, B. 1998. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein. J Lipid Res. 39:925-933.
85. Feron, O., Dessy, C., Desager, J. P., and Balligand, J. L. 2001. Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103:113-118.
86. Ferre, N., Camps, J., Cabre, M., Paul, A., and Joven, J. 2001. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997-1000.
87. Ferre, N., Camps, J., Prats, E., Vilella, E., Paul, A., Figuera, L., and Joven, J. 2002. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48:261-268.
88. Ferretti, G., Bacchetti, T., Marotti, E., and Curatola, G. 2003. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 52:146-151.
89. Finder, J. D., Litz, J. L., Blaskovich, M. A., McGuire, T. F., Qian, Y., Hamilton, A. D., Davies, P., and Sebti, S. M. 1997. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1β in vascular smooth muscle cells. J. Biol. Chem. 272:13484-13488.
90. Fisslthaler, B., Michaelis, U. R., Randriamboavonjy, V., Busse, R., and Fleming, I. 2003. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim. Biophys. Act. 1619:332-339.
91. Folkers, K. 1996. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. Biochem. Biophys. Res. Commun. 224:358-361.
92. Folkers, K., Langsoen, P., Willis, R., Richardson, P., Xia, L. J., Ye, C. Q., and Tamagawa, H. 1990. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. USA 87:8931-8934.
93. Folkers, K., Osterborg, A., Nylander, M., Morita, M., and Mellstedt, H. 1997. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem. Biophys. Res. Commun. 234:296-299.
94. Fontaine, D., Fontaine, J., Dupont, I., Dessy, C., Piech, A., Carpentier, Y., and Berkenboom, G. 2002. Chronic hydroxymethylglutaryl coenzyme a reductase inhibition and endothelial function of the normocholesterolemic rat: comparison with angiotensin-converting enzyme inhibition. J. Cardiovasc. Pharmacol. 40:172-180.
95. Fontaine, D., Otto, A., Fontaine, J., and Berkenboom, G. 2003. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc. Drugs Ther. 17:123-128.
96. Franzoni, F., Quinones-Galvan, A., Regoli, F., Ferrannini, E., and Galetta, F. 2003. A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol. 90:317-321.
97. Fuhrman, B., Koren, L., Volkova, N., Keidar, S., Hayek, T., and Aviram, M. 2002. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164:179-185.
98. Fukui, T., Noma, T., Mizushige, K., Aki, Y., Kimura, S., and Abe, Y. 2000. Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci. 66:2043-2049.
99. Gaist, D., Jeppesen, U., Andersen, M., Garcia Rodriguez, L. A., Hallas, J., and Sindrup, S. H. 2002. Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337.
100. Garg, R., Kumbkarni, Y., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., and Dandona, P. 2000. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36:430-435.
101. Gervais, M., Pons, S., Nicoletti, A., Cosson, C., Giudicelli, J. F., and Richer, C. 2003. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23:183-189.
102. Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., and Littarru, G. P. 1993. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33:226-229.
103. Girnun, G. D., Domann, F. E., Moore, S. A., and Robbins, M. E. 2002. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 16:2793-2801.
104. Girona, J., La Ville, A. E., Sola, R., Plana, N., and Masana, L. 1999. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Cardiol. 83:846-851.
105. Giroux, L. M., Davignon, J., and Naruszewicz, M. 1993. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta 1165:335-338.
106. Glorioso, N., Troffa, C., Filigheddu, F., Dettori, F., Soro, A., Parpaglia, P. P., Collatina, S., and Pahor, M. 1999. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 34:1281-1286.
107. Goalstone, M. L., Wall, K., Leitner, J. W., Kurowski, T., Ruderman, N., Pan, S. J., Ivy, J. L., Moller, D. E., and Draznin, B. 1999. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. Diabetologia 42:310-316.
108. Goli, A. K., Goli, S. A., Byrd, R. P. Jr., and Roy, T. M. 2002. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin. Pharmacol. Ther. 72:461-464.
109. Gouedard, C., Koum-Besson, N., Barouki, R., and Morel, Y. 2003. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 63:945-956.
110. Gregg, D., Rauscher, F. M., and Goldschmidt-Clermont, P. J. 2003. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am. J. Physiol. Cell. Physiol. 285:C723-C734.
111. Grip, O., Janciauskiene, S., and Lindgren, S. 2002. Atorvastatin activates PPARγ and attenuates the inflammatory response in human monocytes. Inflamm. Res. 51:58-62.
112. Gueler, F., Rong, S., Park, J. K., Fiebeler, A., Menne, J., Elger, M., Mueller, D. N., Hampich, F., Dechend, R., Kunter, U., Luft, F. C., and Haller, H. 2002. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J. Am. Soc. Nephrol. 13:2288-2298.
113. Gueraud, F., Alary, J., Costet, P., Debrauwer, L., Dolo, L., Pineau, T., and Paris, A. 1999. In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2- nonenal, using PPARα-deficient mice. J. Lipid Res. 40:152-159.
114. Guerra, R., Zhao, B., Mooser, V., Stafforini, D., Johnston, J. M., and Cohen, J. C. 1997. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J. Lipid Res. 38:2281-2288.
115. Gumieniczek, A. 2003. Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci. 74:553-562.
116. Harker-Murray, A. K., Tajik, A. J., Ishikura, F., Meyer, D., Burnett, J. C., and Redfield, M. M. 2000. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J. Card. Fail. 6:233-242.
117. Hattori, Y., Nakanishi, N., Akimoto, K., Yoshida, M., and Kasai, K. 2003. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23:176-182.
118. Hattori, Y., Nakanishi, N., and Kasai, K. 2002. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res. 54:649-658.
119. Hausding, M., Witteck, A., Rodriguez-Pascual, F., von Eichel-Streiber, C., Forstermann, U., and Kleinert, H. 2000. Inhibition of small G proteins of the rho family by statins or Clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br. J. Pharmacol. 131:553-561.
120. Heeschen, C., Hamm, C. W., Laufs, U., Snapinn, S., Bohm, M., and White, H.D. 2002. Platelet receptor inhibition in ischemic syndrome management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105:1446-1452.
121. Hernandez-Perera, O., Perez-Sala, D., Navarro-Antolin, J., Sanchez-Pascuala, R., Hernandez, G., Diaz, C., and Lamas, S. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101:2711-2719.
122. Hernandez-Perera, O., Perez-Sala, D., Soria, E., and Lamas, S. 2000. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ. Res. 87:616-622.
123. Hoffman, R., Brook, G. J., and Aviram, M. 1992. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 93:105-113.
124. Hofman-Bang, C., Rehnqvist, N., Swedberg, K., Wiklund, I., and Astrom, H. 1995. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J. Card. Fail. 1:101-107.
125. Houten, S. M., Frenkel, J., and Waterham, H. R. 2003. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol. Life Sci. 60:1118-1134.
126. Hrboticky, N., Draude, G., Hapfelmeier, G., Lorenz, R., and Weber, P.C. 1999. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages. Arterioscler. Thromb. Vasc. Biol. 19:1267-1275.
127. Huang, K. C., Chen, C. W., Chen, J. C., and Lin, W. W. 2003. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J. Biomed. Sci. 10:396-405.
128. 2, ciglitazone, and GW1929. Exp. Cell Res. 277:192-200.
129. Human, J. A., Ubbink, J. B., Jerling, J. J., Delport, R., Vermaak, W. J., Vorster, H. H., Lagendijk, J., and Potgieter, H. C. 1997. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin. Chim. Acta 263:67-77.
130. Hussein, O., Schlezinger, S., Rosenblat, M., Keidar, S., and Aviram, M. 1997. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128:11-18.
131. Hussein, O., Shneider, J., Rosenblat, M., and Aviram, M. 2002. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J. Cardiovasc. Pharmacol. 40:28-34.
132. Ichihara, K., and Satoh, K. 2002. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 359:2195-2198.
133. Ichihara, K., Satoh, K., and Abiko, Y. 1993. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J. Cardiovasc. Pharmacol. 22:852-856.
134. Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H., Hirano, K., Kanaide, H., and Takeshita, A. 2001. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21:1896-1901.
135. Ikeda, U., Shimpo, M., Ikeda, M., Minota, S., and Shimada, K. 2001. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J. Cardiovasc. Pharmacol. 38:69-77.
136. Imaeda, A., Aoki, T., Kondo, Y., Hori, M., Ogata, M., Obayashi, H., Hasegawa, G., Nakamura, N., Tokuda, K., Nishino, H., Yoshikawa, T., and Kondo, M. 2001a. Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis. Free Radic. Res. 34:33-44.
137. Imaeda, A., Kaneko, T., Aoki, T., Kondo, Y., Nakamura, N., Nagase, H., and Yoshikawa, T. 2002. Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice. Food Chem. Toxicol. 40:1415-1422.
138. Imaeda, A., Tanigawa, T., Aoki, T., Kondo, Y., Nakamura, N., and Yoshikawa, T. 2001b. Antioxidative effects of fluvastatin and its metabolites against oxidative DNA damage in mammalian cultured cells. Free Radic. Res. 35:789-801.
139. phox message expressions in primary endothelial cells. Metabolism 50:3-11.
140. phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 67:863-876.
141. Inoue, I., Itoh, F., Aoyagi, S., Tazawa, S., Kusama, H., Akahane, M., Mastunaga, T., Hayashi, K., Awata, T., Komoda, T., and Katayama, S. 2002. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem. Biophys. Res. Commun. 290:131-139.
142. 2+-superoxide dismutase in the liver. Life Sci. 63:135-144.
143. Inoue, I., Noji, S., Shen, M. Z., Takahashi, K., and Katayama, S. 1997. The peroxisome proliferator-activated receptor α (PPARα) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochem. Biophys. Res. Commun. 237:606-610.
144. Itoh, S., Umemoto, S., Hiromoto, M., Toma, Y., Tomochika, Y., Aoyagi, S., Tanaka, M., Fujii, T., and Matsuzaki, M. 2002. Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation 105:2288-2295.
145. Jackson, P. R., Wallis, E. J., Haq, I. U., and Ramsay, L. E. 2001. Statins for primary prevention: at what coronary risk is safety assured? Br. J. Clin. Pharmacol. 52:439-446.
146. Jakubowski, H. 1999. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13:2277-2283.
147. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275:3957-3962.
148. Jakubowski, H. 2001. Protein N-homocysteinylation: implications for atherosclerosis. Biomed. Pharmacother. 55:443-447.
149. Jankowski, P., and Kawecka-Jaszcz, K. 2004. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Atherosclerosis 172:191-194.
150. Jarvik, G. P., Rozek, L. S., Brophy, V. H., Hatsukami, T. S., Richter, R. J., Schellenberg, G. D., and Furlong, C. E. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20:2441-2447.
151. Jay, M. T., Chirico, S., Siow, R. C., Bruckdorfer, K. R., Jacobs, M., Leake, D. S., Pearson, J. D., and Mann, G. E. 1997. Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Exp. Physiol. 82:349-360.
152. Jiang, J., and Roman, R. J. 1997. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 30:968-974.
153. Jiao, H. L., and Zhao, B. L. 2002. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol. Appl. Pharmacol. 185:172-179.
154. Jick, H., Zornberg, G. L., Jick, S.S., Seshadri, S., and Drachman, D.A. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
155. Jones, S. P., Trocha, S. D., and Lefer, D. J. 2001. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler. Thromb. Vasc. Biol. 21:2059-2064.
156. Jula, A., Marniemi, J., Huupponen, R., Virtanen, A., Rastas, M., and Ronnemaa, T. 2002. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 287:598-605.
157. Kaesemeyer, W. H., Caldwell, R. B., Huang, J., and Caldwell, R. W. 1999. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33:234-241.
158. Kagota, S., Yamaguchi, Y., Nakamura, K., and Kunitomo, M. 2000. Functional evidence for antioxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta. Clin. Exp. Pharmacol. Physiol. 27:401-405.
159. Kaikkonen, J., Nyyssonen, K., Tuomainen, T. P., Ristonmaa, U., and Salonen, J. T. 1999. Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 443:163-166.
160. Kalinowski, L., Dobrucki, L. W., Brovkovych, V., and Malinski, T. 2002a. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105:933-938.
161. Kalinowski, L., Dobrucki, I. T., and Malinski, T. 2002b. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J. Physiol. Pharmacol. 53:585-595.
162. Kanda, M., Satoh, K., and Ichihara, K. 2003. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol. Pharm. Bull. 26:1681-1684.
163. Kandoussi, A., Martin, F., Hazzan, M., Noel, C., Fruchart, J. C., Staels, B., and Duriez, P. 2002. HMG-CoA reductase inhibition and PPAR-α activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin. Sci. (Lond.) 103 (Suppl 48):81S-83S.
164. Kaneider, N. C., Egger, P., Dunzendorfer, S., and Wiedermann, C. J. 2002. Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler. Thromb. Vasc. Biol. 22:1029-1035.
165. Kanno, T., Abe, K., Yabuki, M., Akiyama, J., Yasuda, T., and Horton, A. A. 1999. Selective inhibition of formyl-methionyl-leucyl-phenylalanine(fMLF)- dependent superoxide generation in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Biochem. Pharmacol. 58:1975-1980.
166. Kano, H., Hayashi, T., Sumi, D., Esaki, T., Asai, Y., Thakur, N.K., Jayachandran, M., and Iguchi, A. 1999. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. Biochem. Biophys. Res. Commun. 259:414-419.
167. Kashiwagi, A., Shinozaki, K., Nishio, Y., Maegawa, H., Maeno, Y., Kanazawa, A., Kojima, H., Haneda, M., Hidaka, H., Yasuda, H., and Kikkawa, R. 1999a. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am. J. Physiol. 277:E976-E983.
168. Kashiwagi, A., Shinozaki, K., Nishio, Y., Okamura, T., Toda, N., and Kikkawa, R. 1999b. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes. Res. Clin. Pract. 45:199-203.
169. Keidar, S., Aviram, M., Maor, I., Oiknine, J., and Brook, J. G. 1994. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br. J. Clin. Pharmacol. 38:513-519.
170. Keidar, S., Kaplan, M., Hoffman, A., and Aviram, M. 1995. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 115:201-215.
171. Kishi, T., Hirooka, Y., Mukai, Y., Shimokawa, H., and Takeshita, A. 2003. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J. Hypertens. 21:379-386.
172. Kobayashi, T., Matsumoto, T., and Kamata, K. 2000. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 131:231-238.
173. Kolyada, A. Y., Fedtsov, A., and Madias, N. E. 2001. 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 38:1024-1029.
174. Kondo, M., Oya-Ito, T., Kumagai, T., Osawa, T., and Uchida, K. 2001. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276:12076-12083.
175. Kothe, H., Dalhoff, K., Rupp, J., Muller, A., Kreuzer, J., Maass, M., and Katus, H. A. 2000. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101:1760-1763.
176. Krum, H., and McMurray, J. J. 2002. Statins and chronic heart failure: do we need a large-scale outcome trial? J. Am. Coll. Cardiol. 39:1567-1573.
177. Kudolo, G. B., Bressler, P., and DeFronzo, R. A. 1997. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J. Lipid. Mediat. Cell Signal. 17:97-113.
178. Kugi, M., Matsunaga, A., Ono, J., Arakowa, K., and Sasaki, J. 2002. Antioxidative effects of fluvastatin on superoxide anion activated by angiotensin II in human aortic smooth muscle cells. Cardiovasc. Drug. Ther. 16:203-207.
179. Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., and Walsh, K. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6:1004-1010.
180. Kurusu, A., Shou, I., Nakamura, S., Fukui, M., Shirato, I., and Tomino, Y. 2000. Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin. Exp. Pharmacol. Physiol. 27:767-770.
181. Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Harkonen, M., Tikkanen, M. J., and Himberg, J. J. 1996. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 77:851-854.
182. Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., and Himberg, J. J. 1995. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Ther. 57:62-66.
183. 10. A review of animal and human publications. Biofactors 18:101-111.
184. Lankin, V. Z., Tikhaze, A. K., Konovalova, G. G., Tutunov, V. S., Medvedeva, N. V., Kotkina, T. I., Kukharchuk, V. V., and Belenkov, Y. N. 2002. Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta- methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol. Bull. Exp. Biol. Med. 134:39-42.
185. Lankin, V. Z., Tikhaze, A. K., Kukharchuk, V. V., Konovalova, G. G., Pisarenko, O. I., Kaminnyi, A. I., Shumaev, K. B., and Belenkov, Y. N. 2003. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins. Mol. Cell. Biochem. 249:129-140.
186. Laufs, U., Endres, M., Custodis, F., Gertz, K., Nickenig, G., Liao, J. K., and Bohm, M. 2000. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102:3104-3110.
187. Laufs, U., La Fata, V., Plutzky, J., and Liao, J. K. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135.
188. Laufs, U., and Liao, J. K. 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:24266-24271.
189. Laufs, U., Wassmann, S., Hilgers, S., Ribaudo, N., Bohm, M., and Nickenig, G. 2001. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am. J. Cardiol. 88:1306-1307.
190. 2α formation. J. Cardiovasc. Pharmacol. 40:868-874.
191. Lefer, A. M., Campbell, B., Shin, Y. K., Scalia, R., Hayward, R., and Lefer, D. J. 1999. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100:178-184.
192. Legendre, C., Causse, E., Chaput, E., Salvayre, R., Pineau, T., and Edgar, A. D. 2002. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARα-mediated effect. Biochem. Biophys. Res. Commun. 295:1052-1056.
193. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J. Biol. Chem. 277:29681-29685.
194. Leonhardt, W., Kurktschiev, T., Meissner, D., Lattke, P., Abletshauser, C., Weidinger, G., Jaross, W., and Hanefeld, M. 1997. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur. J. Clin. Pharmacol. 53:65-69.
195. Lewis, S. J., Sacks, F. M., Mitchell, J. S., East, C., Glasser, S., Kell, S., Letterer, R., Limacher, M., Moye, L. A., Rouleau, J. L., Pfeffer, M. A., and Braunwald, E. 1998. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J. Am. Coll. Cardiol. 32:140-146.
196. Levy, B. D., Petasis, N. A., and Serhan, C. N. 1997. Polyisoprenyl phosphates in intracellular signalling. Nature 389:985-990.
197. Li, D., Chen, H., Romeo, F., Sawamura, T., Saldeen, and T., Mehta, J. L. 2002. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J. Pharmacol. Exp. Ther. 302:601-605.
198. Li, D. Y., Chen, H. J., and Mehta, J. L. 2001. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc. Res. 52:130-135.
199. Li, L., Fink, G. D., Watts, S. W., Northcott, C. A., Galligan, J. J., Pagano, P. J., and Chen, A. F. 2003. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107:1053-1058.
200. Liao, J. K. 2002. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 86:5-18.
201. Lo, Y. L., Leoh, T. H., Loh, L. M., and Tan, C.E. 2003. Statin therapy and small fibre neuropathy: a serial electrophysiological study. J. Neurol. Sci. 208:105-108.
202. Loop, R. A., Anthony, M., Willis, R. A., and Folkers, K. 1994. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. Mol. Aspects Med. 15 (Suppl):S195-S206.
203. Lu, T. T., Repa, J. J., and Mangelsdorf, D.J. 2001. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J. Biol. Chem. 276:37735-37738.
204. 2+ channel by targeting the α 1C subunit. Arterioscler. Thromb. Vasc. Biol. 19:959-966.
205. Luftjohann, D., Sigit, J. I., Locatelli, S., von Bergmann, K., and Schmidt, H. H. 2001. High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia. Atherosclerosis 155:265-266.
206. Maack, C., Kartes, T., Kilter, H., Schafers, H. J., Nickenig, G., Bohm, M., and Laufs, U. 2003. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108:1567-1574.
207. Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. H., Hill, E., Roberts, C., Durrington, P. N., and Mackness, M. I. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21:1451-1457.
208. Mackness, B., Hunt, R., Durrington, P. N., and Mackness, M. I. 1997. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1233-1238.
209. Mackness, M. I., Harty, D., Bhatnagar, D., Winocour, P. H., Arrol, S., Ishola, M., and Durrington, P. N. 1991. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86:193-199.
210. Mackness, M. I., Mackness, B., and Durrington, P. N. 2002. Paraoxonase and coronary heart disease. Atheroscler Suppl. 3:49-55.
211. Maggio, D., Barabani, M., Pierandrei, M., Polidori, M. C., Catani, M., Mecocci, P., Senin, U., Pacifici, R., and Cherubini, A. 2003. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J. Clin. Endocrinol. Metab. 88:1523-1527.
212. Martin, G., Duez, H., Blanquart, C., Berezowski, V., Poulain, P., Fruchart, J. C., Najib-Fruchart, J., Glineur, C., and Staels, B. 2001. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107:1423-1432.
213. Martinez-Castelao, A., Grinyo, J. M., Fiol, C., Castineiras, M. J., Hurtado, I., Gil-Vernet, S., Seron, D., Porta, I., Minarro, A., Villarroya, A., and Alsina, J. 1999. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Kidney Int. 54(Suppl. 71):S231-S234.
214. Martinez-Gonzalez, J., Vinals, M., Vidal, F., Llorente-Cortes, V., and Badimon, L. 1997. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis 135:213-223.
215. Marz, W., Siekmeier, R., Muller, H. M., Wieland, H., Gross, W., and Olbrich, H. G. 2000. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. 5:275-279.
216. McCarty, M. F. 1999. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med. Hypotheses 53:300-304.
217. McCarty, M. F. 2002. Insulin's stimulation of endothelial superoxide generation may reflect up-regulation of isoprenyl transferase activity that promotes rac translocation. Med. Hypotheses 58:472-475.
218. McGuire, T. F., Xu, X. Q., Corey, S. J., Romero, G. G., and Sebti, S. M. 1994. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem. Biophys. Res. Commun. 204:399-406.
219. Mehta, J. L., Li, D. Y., Chen, H. J., Joseph, J., and Romeo, F. 2001. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem. Biophys. Res. Commun. 289:857-861.
220. Melenovsky, V., Malik, J., Wichterle, D., Simek, J., Pisarikova, A., Skrha, J., Poledne, R., Stavek, P., and Ceska, R. 2002. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am. Heart. J. 144:E6.
221. Miltiadous, G., Papakostas, J., Chasiotis, G., Seferiadis, K., and Elisaf, M. 2003. Statins and homocysteine. Atherosclerosis 166:199-200.
222. Ming, X. F., Viswambharan, H., Barandier, C., Ruffieux, J., Kaibuchi, K., Rusconi, S., and Yang, Z. 2002. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 22:8467-8477.
223. Mital, S., Zhang, X., Zhao, G., Bernstein, R. D., Smith, C. J., Fulton, D. L., Sessa, W. C., Liao, J. K., and Hintze, T. H. 2000. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am. J. Physiol. Heart Circ. Physiol. 279:H2649-H2657.
224. Mitani, H., Bandoh, T., Ishikawa, J., Kimura, M., Totsuka, T., and Hayashi, S. 1996. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br. J. Pharmacol. 119:1269-1275.
225. Mitani, H., Egashira, K., Ohashi, N., Yoshikawa, M., Niwa, S., Nonomura, K., Nakashima, A., and Kimura, M. 2003. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Pharmacology 68:121-130.
226. Mitani, H., and Kimura, M. 2003. Preservation of endothelium-dependent and Nω-nitro-L-arginine methyl ester- and indomethacin-resistant arterial relaxation in high-cholesterol-diet fed rabbits by treatment with fluvastatin, an HMG-CoA reductase inhibitor. J. Cardiovasc. Pharmacol. 42:55-62.
227. Montero, M. T., Hernandez, O., Suarez, Y., Matilla, J., Ferruelo, A. J., Martinez-Botas, J., Gomez-Coronado, and D., Lasuncion, M. A. 2000. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153:303-313.
228. Moriyama, T., Kawada, N., Nagatoya, K., Takeji, M., Horio, M., Ando, A., Imai, E., and Hori, M. 2001. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 59:2095-3103.
229. Mortensen, S. A. 2000. Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. J. Am. Coll. Cardiol. 36:304-305.
230. Mortensen, S. A., Leth, A., Agner, E., and Rohde, M. 1997. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol. Aspects Med. 18 (Suppl): S137-S144.
231. Mukai, Y., Shimokawa, H., Matoba, T., Hiroki, J., Kunihiro, I., Fujiki, T., and Takeshita, A. 2003. Acute vasodilator effects of HMG-CoA reductase inhibitors: involvement of PI3-kinase/Akt pathway and Kv channels. J. Cardiovasc. Pharmacol. 42:118-124.
232. Muniyappa, R., Xu, R., Ram, J. L., and Sowers, J. R. 2000. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am. J. Physiol. Heart. Circ. Physiol. 278:H1762-H1768.
233. Muramatsu, J., Kobayashi, A., Hasegawa, N., and Yokouchi, S. 1997. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 130:179-182.
234. Najib, S., and Sanchez-Margalet, V. 2001. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J. Mol. Endocrinol. 27:85-91.
235. Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I., and Osame, M. 1998. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 152:99-106.
236. Nakamura, T., Nishi, H., Kokusenya, Y., Hirota, K., and Miura, Y. 2000. Mechanism of antioxidative activity of fluvastatin-determination of the active position. Chem. Pharm. Bull. 48:235-237.
237. Nakamura, T., Ushiyama, C., Hirokawa, K., Osada, S., Shimada, N., and Koide, H. 2001. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am. J. Nephrol. 21:449-454.
238. Nakashima, A., Ohtawa, M., Iwasaki, K., Wada, M., Kuroda, N., and Nakashima, K. 2001. Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species. Life Sci. 69:1381-1389.
239. Navab, M., Hama-Levy, S., Van Lenten, B. J., Fonarow, G. C., Cardinez, C. J., Castellani, L. W., Brennan, M. L., Lusis, A. J., Fogelman, A. M., and La Du, B. N. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:2005-2019.
240. Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., and Takeshita, A. 2001. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89:415-421.
241. Nickenig, G., Baumer, A. T., Temur, Y., Kebben, D., Jockenhovel, F., and Bohm, M. 1999. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100:2131-2134.
242. Norata, G. D., Pirillo, A., and Catapano, A. L. 2003. Statins and oxidative stress during atherogenesis. J. Cardiovasc. Risk. 10:181-189.
243. Noto, H., Hashimoto, Y., Satoh, H., Hara, M., Iso-o, N., Togo, M., Kimura, S., and Tsukamoto, K. 2001. Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem. Biophys. Res. Commun. 289:395-401.
244. Obata, T., Ebihara, A., and Yamanaka, Y. 2000. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, resists hydroxyl radical generation in the rat myocardium. J. Pharm. Pharmacol. 52:425-430.
245. Obata, T., and Yamanaka, Y. 2000. Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res. 860:166-169.
246. O'Donnell, M. P., Kasiske, B. L., Katz, S. A., Schmitz, P. G., Keane, W. F. 1992. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20:651-658.
247. Ohrvall, M., Lithell, H., Johansson, J., and Vessby, B. 1995. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 44:212-217.
248. Oranje, W. A., Sels, J. P., Rondas-Colbers, G. J., Lemmens, P. J., and Wolffenbuttel, B. H. 2001. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin. Chim. Acta 311:91-94.
249. Pahan, K., Sheikh, F. G., Namboodiri, A. M., and Singh, I. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100:2671-2679.
250. Paiva, H., Laakso, J., Lehtimaki, T., Isomustajarvi, M., Ruokonen, I., and Laaksonen, R. 2003. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 41:219-222.
251. Paiva, H., Laakso, J., Lehtimaki, T., and Laaksonen, R. 2002. Agressive lipid-lowering with statins and skeletal muscle ubiquinone: a randomised, controlled trial: Atherosclerosis (Suppl 3):147-148.
252. Palinski, W., and Napoli, C. 2002. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler. Thromb. Vasc. Biol. 22:1745-1750.
253. Palomaki, A., Malminiemi, K., Malminiemi, O., and Solakivi, T. 1999. Effects of lovastatin therapy on susceptibility of LDL to oxidation during α-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol. 19:1541-1548.
254. Palomaki, A., Malminiemi, K., and Metsa-Ketela, T. 1997. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett. 410:254-258.
255. Palomaki, A., Malminiemi, K., Solakivi, T., and Malminiemi, O. 1998. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J. Lipid Res. 39:1430-1437.
256. Park, J. K., Muller, D. N., Mervaala, E. M., Dechend, R., Fiebeler, A., Schmidt, F., Bieringer, M., Schafer, O., Lindschau, C., Schneider, W., Ganten, D., Luft, F. C., and Haller, H. 2000. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 58:1420-1430.
257. Parker, R.A., Huang, Q., and Tesfamariam, B. 2003. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 169:19-29.
258. Pasternak, R. C., Smith, S. C. Jr, Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., and Lenfant, C. 2002. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. 40:567-572.
259. Patel, R. P., Levonen, A., Crawford, J. H., and Darley-Usmar, V. M. 2000. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovasc. Res. 47:465-474.
260. Pereira, E. C., Bertolami, M. C., Faludi, A. A., Salem, M., Bersch, D., and Abdalla, D. S. 2003. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic. Res. 37:529-536.
261. Perez-Guerrero, C., Alvarez de Sotomayor, M., Jimenez, L., Herrera, M. D., and Marhuenda, E. 2003. Effects of simvastatin on endothelial function after chronic inhibition of nitric oxide synthase by L-NAME. J. Cardiovasc. Pharmacol. 42:204-210.
262. Pietsch, A., Erl, W., and Lorenz, R. L. 1996. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52:433-439.
263. Pizzi, C., Manfrini, O., Fontana, F., and Bugiardini, R. 2004. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation 109:53-58.
264. Portakal, O., Ozkaya, O., Erden Inal, M., Bozan, B., Kosan, M., and Sayek, I. 2000. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin. Biochem. 33: 279-284.
265. Poynter, M. E., and Daynes, R.A. 1998. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273:32833-32841.
266. Pritchard, K. A. Jr., Groszek, L., Smalley, D. M., Sessa, W. C., Wu, M., Villalon, P., Wolin, M. S., and Stemerman, M. B. 1995. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 77:510-518.
267. Puccetti, L., Pasqui, A. L., Pastorelli, M., Bova, G., Cercignani, M., Palazzuoli, A., Angori, P., Auteri, A., and Bruni, F. 2002. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur. J. Clin. Invest. 32:901-908.
268. Puccetti, L., Pasqui, A. L., Pastorelli, M., Bova, G., Di Renzo, M., Leo, A., Cercignani, M., Palazzuoli, A., Auteri, A., and Bruni, F. 2003. Platelet hyperactivity after statin treatment discontinuation. Thromb. Haemost. 90:476-482.
269. Ray, D. E., and Richards, P. G. 2001. The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicol Lett. 120:343-351.
270. Ridker, P. M., Shih, J., Cook, T. J., Clearfield, M., Downs, J. R., Pradhan, A. D., Weis, S. E., and Gotto, A. M. Jr. 2002. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 105:1776-1779.
271. Rikitake, Y., Kawashima, S., Takeshita, S., Yamashita, T., Azumi, H., Yasuhara, M., Nishi, H., Inoue, N., and Yokoyama, M. 2001. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154:87-96.
272. Rodrigo, L., Hernandez, A. F., Lopez-Caballero, J.J., Gil, F., and Pla, A. 2001. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem. Biol. Int. 137:123-137.
273. Roglans, N., Sanguino, E., Peris, C., Alegret, M., Vazquez, M., Adzet, T., Diaz, C., Hernandez, G., Laguna, J. C., and Sanchez, R. M. 2002. Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J. Pharmacol. Exp. Ther. 302:232-239.
274. Rosen, G. M., Pou, S., Ramos, C. L., Cohen, M. S., and Britigan, B. E. 1995. Free radicals and phagocytic cells. FASEB J. 9:200-209.
275. 2+-ATPase activities. J. Hypertens. 15:1723-1728.
276. 2+ channels in vascular smooth muscle cells. J. Biol. Chem. 272:32240-32246.
277. Roullet, J. B., Xue, H., Chapman, J., McDougal, P., Roullet, C. M., and McCarron, D. A. 1996. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest. 97:2384-2390.
278. Roullet, J. B., Xue, H., Pappu, A. S., Roullet, C., Holcomb, S., and McCarron, D.A. 1993. Mevalonate availability and cardiovascular functions. Proc. Natl. Acad. Sci. USA 90:11728-11732.
279. Roullet, J. B., Xue, H., Roullet, C. M., Fletcher, W. S., Cipolla, M. J., Harker, C. T., and McCarron, D. A. 1995. Mevalonate availability affects human
280. Rousseau, G., Desrosiers, C., and Varin, F. 1998. A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr. Ther. Res. 59:666-679.
281. Rousseau, G., Véronneau, M., DesRosiers, C., and Varin, F. 1999. Effects of lovastatin and pravastatin on ubiquinone and 4-hydroxynonenal tissue levels in the hypercholesterolemic hamster. Curr. Ther. Res. 60:87-104.
282. Rueckschloss, U., Galle, J., Holtz, J., Zerkowski, H. R., and Morawietz, H. 2001. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104:1767-1772.
283. Sacher, H. L., Sacher, M. L., Landau, S. W., Kersten, R., Dooley, F., Sacher, A., Sacher, M., Dietrick, K., and Ichkhan, K. 1997. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am. J. Ther. 4:66-72.
284. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., and Braunwald, E. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335:1001-1009.
285. Sadeghi, M. M., Collinge, M., Pardi, R., and Bender, J. R. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165:2712-2718.
286. Sanchez-Quesada, J. L., Otal-Entraigas, C., Franco, M., Jorba, O., Gonzalez-Sastre, F., Blanco-Vaca, F., and Ordonez-Llanos, J. 1999. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 84:655-659.
287. Sanguigni, V., Pignatelli, P., Caccese, D., Pulcinelli, F. M., Lenti, L., Magnaterra, R., Martini, F., Lauro, R., and Violi, F. 2002. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb. Haemost. 87:796-801.
288. Sasaki, S., Kuwahara, N., Kunitomo, K., Harada, S., Yamada, T., Azuma, A., Takeda, K., and Nakagawa, M. 2002. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol. 89:386-389.
289. Satoh, K., and Ichihara, K. 1995. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts. Eur. J. Pharmacol. 292:271-275.
290. Satoh, K., and Ichihara, K. 2000. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J. Cardiovasc. Pharmacol. 35:256-262.
291. Satoh, K., Shirota, F., Tsunajima, T., Beinlich, C. J., Morgan, H. E., and Ichihara, K. 2001. Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin. Am. J. Physiol. Heart Circ. Physiol. 280:H2746-H2751.
292. Satoh, K., Yamato, A., Nakai, T., Hoshi, K., and Ichihara, K. 1995. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br. J. Pharmacol. 116:1894-1898.
293. Sawamura, M., Nara, Y., and Yamori, Y. 1992. Liver mevalonate 5-pyrophosphate decarboxylase is responsible for reduced serum cholesterol in stroke-prone spontaneously hypertensive rat. J. Biol. Chem. 267:6051-6055.
294. Scatena, R., Nocca, G., De Sole, P., Fresu, R., Zuppi, C., and Giardina, B. 1997. The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leucocytes. An intriguing side effect. Clin. Chim. Acta 266:173-183.
295. Schaefer, W. H., Lawrence, J. W., Loughlin, A. F., Stoffregen, D. A., Mixson, L. A., Dean, D. C., Raab, C. E., Yu, N. X., Lankas, G. R., and Frederick, C.B. 2004. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol. Appl. Pharmacol. 194:10-23.
296. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., Kamper, A. M., Macfarlane, P. W., Meinders, A. E., Norrie, J., Packard, C. J., Perry, I. J., Stott, D. J., Sweeney, B. J., Twomey, C., and Westendorp, R. G. 2002. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630.
297. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., and Packard, C. J. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1301-1307.
298. Shishehbor, M. H., Aviles, R. J., Brennan, M. L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F. Jr., Penn, M. S., Sprecher, D. L., Vita, J. A., and Hazen, S.L. 2003a. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289:1675-1680.
299. Shishehbor, M. H., Brennan, M. L., Aviles, R. J., Fu, X., Penn, M. S., Sprecher, D. L., and Hazen, S. L. 2003b. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108:426-431.
300. Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., Ueno, T., and Sata, M. 2003. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37:136-147.
301. Simko, F., Matuskova, J., Luptak, I., Krajcirovicova, K., Kucharska, J., Gvozdjakova, A., Babal, P., and Pechanova, O. 2004. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci. 74:1211-1224.
302. Sinatra, S. T. 1999. "Care," cancer and coenzyme Q10. J. Am. Coll. Cardiol. 33:897-899.
303. Sindermann, J. R., Fan, L., Weigel, K. A., Troyer, D., Muller, J. G., Schmidt, A., March, K. L., and Breithardt, G. 2000. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 150:331-341.
304. Singh, R. B., Singh, N. K., Rastogi, S. S., Wander, G. S., Aslam, M., Onouchi, Z., Kummerow, F. A., and Nangia, S. 1997. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc. Drug. Ther. 11:575-590.
305. Sinzinger, H. 2000. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? Atherosclerosis 149:225.
306. Sinzinger, H. 2002. Flu-like response on statins. Med. Sci. Monit. 8:CR384-CR388.
307. Sinzinger, H., Chehne, F., and Lupattelli, G. 2002a. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf. 25:877-883.
308. Sinzinger, H., Lupattelli, G., and Chehne, F. 2000. Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 153:255-256.
309. 2α is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J. Clin. Pharm. Ther. 26:303-310.
310. Sinzinger, H., Wolfram, R., and Peskar, B.A. 2002b. Muscular side effects of statins. J Cardiovasc Pharmacol. 40:163-171.
311. Skaletz-Rorowski, A., Lutchman, M., Kureishi, Y., Lefer, D. J., Faust, J. R., and Walsh, K. 2003. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc. Res. 57:253-264.
312. Sörenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C., Billecke, S., and La Du, B.N. 1999. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19:2214-2225.
313. Sumi, D., Hayashi, T., Thakur, N. K., Jayachandran, M., Asai, Y., Kano, H., Matsui, H., and Iguchi, A. 2001. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155:347-357.
314. Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., and Weber, K. T. 2002. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161:1773-1781.
315. Suzumura, K., Kasahara, E., Ohnishi, Y., Chien, K. C., and Inoue, M. 2000a. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits. Clin. Exp. Pharmacol. Physiol. 27:709-714.
316. Suzumura, K., Ohashi, N., Oka, K., Yasuhara, M., and Narita, H. 2001. Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters. Free Radic. Res. 35:815-823.
317. Suzumura, K., Tanaka, K., Yasuhara, M., and Narita, H. 2000b. Inhibitory effect of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoproteins. Biol. Pharm. Bull. 23:873-878.
318. Suzumura, K., Yasuhara, M., and Narita, H. 1999a. Superoxide anion scavenging properties of fluvastatin and its metabolites. Chem. Pharm. Bull. 47:1477-1480.
319. Suzumura, K., Yasuhara, M., Tanaka, K., Odawara, A., Narita, H., and Suzuki, T. 1999b. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem. Pharm. Bull. 47:1010-1012.
320. Suzumura, K., Yasuhara, M., Tanaka, K., and Suzuki, T. 1999c. In vitro inhibitory effects of the optical isomers and metabolitem of fluvastatin in copper ion-induced LDL oxidation. Biol. Pharm. Bull. 22:971-974.
321. Suzumura, K., Yasuhara, M., Tanaka, K., and Suzuki, T. 1999d. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem. Pharmacol. 57:697-703.
322. Sydow, K., and Munzel, T. 2003. ADMA and oxidative stress. Atherosclerosis 4(Suppl):41-51.
323. Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M., Takemoto, Y., Kitakaze, M., and Liao, J. K. 2001. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108:1429-1437.
324. Tamura, A., Watanabe, T., and Nasu, M. 2003. Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ. J. 67:816-820.
325. Thakur, N. K., Hayashi, T., Sumi, D., Kano, H., Tsunekawa, T., and Iguchi, A. 2001. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 281:H75-H83.
326. Thompson, P. D., Clarkson, P., and Karas, R. H. 2003. Statin-associated myopathy. JAMA 289:1681-1690.
327. Tiefenbacher, C. P., Kapitza, J., Dietz, V., Lee, C. H., and Niroomand, F. 2003. Reduction of myocardial infarct size by fluvastatin. Am. J. Physiol. Heart Circ. Physiol. 285:H59-H64.
328. Tomas, M., Senti, M., Garcia-Faria, P., Vila, J., Torrents, A., Covas, M., and Marrugat, J. 2000. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20:2113-2119.
329. Tomiyama, K., Nishio, E., and Watanabe, Y. 1999. Both wortmannin and simvastatin inhibit the adipogenesis in 3T3-L1 cells during the late phase of differentiation. Jpn. J. Pharmacol. 80:375-378.
330. Transon, C., Leemann, T., and Dayer, P. 1996. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:209-215.
331. Transon, C., Leemann, T., Vogt, N., and Dayer, P. 1995. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin. Pharmacol. Ther. 58:412-417.
332. 2, platelet activating factor-acetylhydrolase. Atherosclerosis 3(Suppl):57-68.
333. Tsimihodimos, V., Karabina, S. A., Tambaki, A. P., Bairaktari, E., Goudevenos, J. A., Chapman, M. J., Elisaf, M., and Tselepis, A. D. 2002a. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22:306-311.
334. Tsimihodimos, V., Karabina, S. A., Tambaki, A. P., Bairaktari, E., Miltiadous, G., Goudevenos, J. A., Cariolou, M. A., Chapman, M. J., Tselepis, A. D., and Elisaf, M. 2002b. Altered distribution of platelet-activating factor- acetyl-hydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 43:256-263.
335. Tsunekawa, T., Hayashi, T., Kano, H., Sumi, D., Matsui-Hirai, H., Thakur, N.K., Egashira, K., and Iguchi, A. 2001. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379.
336. Umetani, N., Kanayama, Y., Okamura, M., Negoro, N., and Takeda, T. 1996. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim. Biophys. Acta 1303:199-206.
337. Usui, H., Shikata, K., Matsuda, M., Okada, S., Ogawa, D., Yamashita, T., Hida, K., Satoh, M., Wada, J., and Makino, H. 2003. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol. Dial. Transplant. 18:265-272.
338. Valkonen, V. P., Laakso, J., Paiva, H., Lehtimaki, T., Lakka, T. A., Isomustajarvi, M., Ruokonen, I., Salonen, J. T., and Laaksonen, R. 2003. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atherosclerosis 4(Suppl):19-22.
339. Vasquez-Vivar, J., Kalyanaraman, B., Martasek, P., Hogg, N., Masters, B.S., Karoui, H., Tordo, P., and Pritchard, K.A. Jr. 1998. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA 95:9220-9225.
340. Vaziri, N. D., Ni, Z., Oveisi, F., and Trnavsky-Hobbs, D. L. 2000. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36:957-964.
341. Vazquez, M., Merlos, M., Adzet, T., and Laguna, J. C. 1996. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. Br. J. Pharmacol. 117:1155-1162.
342. Vecchione, C., and Brandes, R. P. 2002. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91:173-179.
343. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R.M., and Schiffrin, E. L. 2002. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510.
344. Von Knethen, A. A., and Brune, B. 2001. Delayed activation of PPARγ by LPS and IFN-γ attenuates the oxidative burst in macrophages. FASEB J. 15:535-544.
345. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J. C., Laudet, V., and Staels, B. 1998. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erb α mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273:25713-25720.
346. Wagner, A. H., Kohler, T., Ruckschloss, U., Just, I., and Hecker, M. 2000. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20:61-69.
347. Wagner, A. H., Schwabe, O., and Hecker, M. 2002. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 136:143-149.
348. Wagstaff, L. R., Mitton, M. W., Arvik, B. M., and Doraiswamy, P. M. 2003. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23: 871-880.
349. Wassmann, S., Laufs, U., Baumer, A. T., Muller, K., Ahlbory, K., Linz, W., Itter, G., Rosen, R., Bohm, M., and Nickenig, G. 2001a. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37:1450-1457.
350. Wassmann, S., Laufs, U., Baumer, A.T., Muller, K., Konkol, C., Sauer, H., Bohm, M., and Nickenig, G. 2001b. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 59:646-654.
351. Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, A. T., Linz, W., Bohm, M., and Nickenig, G. 2002. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22:300-305.
352. White, C. R., Darley-Usmar, V., Berrington, W. R., McAdams, M., Gore, J. Z., Thompson, J. A., Parks, D. A., Tarpey, M. M., and Freeman, B. A. 1996. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. USA 93:8745-8749.
353. Willis, R. A., Folkers, K., Tucker, J. L., Ye, C. Q., Xia, L. J., and Tamagawa, H. 1990. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. USA 87:8928-8930.
354. Wilson, S. H., Chade, A. R., Feldstein, A., Sawamura, T., Napoli, C., Lerman, A., and Lerman, L.O. 2003. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol. Dial. Transplant. 18:703-709.
355. Wilson, S. H., Simari, R. D., Best, P. J., Peterson, T. E., Lerman, L. O., Aviram, M., Nath, K. A., Holmes, D. R. Jr., and Lerman, A. 2001. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 21:122-128.
356. Wilson, T. W., Alonso-Galicia, M., and Roman, R. J. 1998. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31:225-231.
357. 2+/calmodulin- dependent and tetrahydrobiopterin regulatory process. J. Biol. Chem. 273:25804-25808.
358. Xu, C. B., Stenman, E., and Edvinsson, L. 2002. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem. Pharmacol. 64:497-505.
359. Yamaguchi, Y., Matsuno, S., Kagota, S., Haginaka, J., and Kunitomo, M. 2002. Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress. Eur. J. Pharmacol. 436:97-105.
360. Yamamoto, A., Hoshi, K., and Ichihara, K. 1998. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur. J. Pharmacol. 361:143-149.
361. Yamamoto, A., Ichihara, K., and Hoshi, K. 2001. Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes. J. Pharm. Pharmacol. 53:227-232.
362. Yang, Z., Kozai, T., van der Loo, B., Viswambharan, H., Lachat, M., Turina, M.I., Malinski, T., and Luscher, T. F. 2000. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll. Cardiol. 36:1691-1697.
363. Yasuhara, M., Suzumura, K., Tanaka, H., Takahashi, M., Aoki, S., and Odawara, A. 2000. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification In hypercholesterolaemic rabbits. Biol. Pharm. Bull. 23:570-574.
364. Yasunari, K., Maeda, K., Minami, M., and Yoshikawa, J. 2001. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler. Thromb. Vasc. Biol. 21:937-942.
365. Yoshida, H., Ishikawa, T., Ayaori, M., Shige, H., Hosoai, H., and Nishio, E. 1995. Effects of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. Clin. Ther. 17:379.
366. Yoshida, H., Ishikawa, T., Ayaori, M., Shige, H., Ito, T., Suzukawa, M., and Nakamura, H. 1998. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 139:179-187.
367. Zambrana, J. L., Lopez-Miranda, J., Blanco, A., Arizon, J. M., Jansen, S., Paniagua, J. A., Jimenez-Pereperez, J. A., Concha, M., and Perez-Jimenez, F. 1998. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. J. Heart Lung Transplant. 17:1213-1219.
368. Zelvyte, I., Dominaitiene, R., Crisby, M., and Janciauskiene, S. 2002. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 45:147-154.
369. Zoja, C., Corna, D., Rottoli, D., Cattaneo, D., Zanchi, C., Tomasoni, S., Abbate, M., and Remuzzi, G. 2002. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 61:1635-1645.